A Phase 2/3 interventional study of Paclitaxel and cisplatin in Head and Neck Cancer, sponsored by Bristol-Myers Squibb. Completed at 2 sites in Korea, Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-02-04.
Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing paclitaxel in Head and Neck Neoplasms — 8 open to participants now, 11 under way, none of them phase 3. Paclitaxel · Head and Neck Neoplasms.
Among the 61 studies testing paclitaxel in Head and Neck Neoplasms, this one is the 20th largest by enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2005, is the only one in phase 2/3, and was the 26th registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →8 of the 61 studies testing paclitaxel in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75
Barbara Ann Karmanos Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 48 · Phase 3 4
First in 1988; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is close to the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 40 across the 55 interventional studies. Of the 43 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 61 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
18 studies in Head and Neck Neoplasms by Bristol-Myers Squibb: 1 open now, 1 under way, none of them phase 3. Of 16 finished, 4 (25%) have results posted.
Among the 18 studies in Head and Neck Neoplasms by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2005, is the only one in phase 2/3, and was the 1st registered.
Bristol-Myers Squibb’s Head and Neck Neoplasms studies by the year they started, since 2004.
3 of the studies testing paclitaxel in Head and Neck Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05420948University of ChicagoA Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer | 2026-12-01 |
| NCT06793761Beijing Tongren HospitalA Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC | 2026-12-20 |
| NCT05358548Rutgers, The State University of New JerseyATATcH Alternating Treatment Plans for Advanced Cancer | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 61 studies testing paclitaxel in Head and Neck Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 18 in Head and Neck Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn if a paclitaxel-cisplatin combination regimen given in the neoadjuvant setting is active in locally advanced head and neck cancer. the safety of this treatment will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Paclitaxel · Drug: cisplatin
Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
Tumor response rate of locally advanced head and neck cancer to a paclitaxel-cisplatin combination regimen in a neoadjuvant setting and administered during maximum 3 cycles.
Toxicity for maximum 3 cycles
The record gives a start of May 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paclitaxel · Cisplatin